Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

3 Best Vanguard Dividend ETFs for Reliable Passive Income in 2026

Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis